It is required to optimize adequate biomarkers that can help with proper patient selection, such as tumor PD-L1 status, mutational burden (TMB), or the percentage of tumor-infiltrating lymphocytes (TILs) [101]. This evidence concerns the gene CD274 and neoplasm.